A

Accurate Clinical Management | Houston Rheumatology Center

Research site

(Unclaimed)

Location

3800 Emmett Hutto Boulevard, Baytown, Texas, United States of America

Site insights

Top conditions

Top treatments

Adalimumab

Methotrexate

Baricitinib

Upadacitinib

LY3009104

ABT-494

Peresolimab

Pf-06650833

Ixekizumab

LY3471851

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis...

Enrolling

Rheumatoid Arthritis

Drug: LY3541860

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome (Unity)

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Dise...

Enrolling

Primary Sjogrens Disease

Biological: Efgartigimod PH20 SC

Other: Placebo PH20 SC

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Active, not recruiting

Obesity

Psoriatic Arthritis

Drug: Tirzepatide

Drug: Ixekizumab

Study of GS-0151 in Participants With Rheumatoid Arthritis

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This w...

Enrolling

Rheumatoid Arthritis

Drug: GS-0151

Drug: Placebo